Close Menu

NEW YORK (360Dx) – When Abhi Gholap now thinks about a company that he sold to Roche in 2010 for $100 million, he sees that the market may not have been quite ready for digital pathology at the time.

But seven years after selling that company called BioImagene, the space has evolved and where healthcare professionals once weren't quite sure about the advantages of using digital pathology technology, Gholap now sees an opportunity for on-demand, cloud-based digital services, he said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.